Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial

Jean Louis Vincent, Derek C. Angus, Antonio Artigas, Andre C Kalil, Bruce R. Basson, Hassan H. Jamal, Gerald Johnson, Gordon R. Bernard

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

Objective: To assess morbidity in patients with severe sepsis managed with and without drotrecogin alfa (activated). Design: Analysis of secondary end points in a prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (PROWESS). Setting: A total of 164 medical institutions in 11 countries. Patients: A total of 1,690 consecutive adult patients with severe sepsis. Interventions: A 96-hr infusion of drotrecogin alfa (activated) (human recombinant activated protein C) or placebo. Measurements and Main Results: Sequential Organ Failure Assessment (SOFA) scores for cardiovascular, respiratory, renal, hematologic, and hepatic organ systems were measured for 28 days. Mean cardiovascular SOFA scores were significantly lower for patients treated with drotrecogin alfa (activated) compared with placebo patients over this time period (p = .022). Drotrecogin alfa (activated)-treated patients also showed significantly faster resolution of cardiovascular (p = .009) and respiratory (p = .009) dysfunction and significantly slower onset of hematologic organ dysfunction (p = .041) compared with placebo patients for days 1 to 7. No significant differences in morbidity were observed between treatment groups among 28-day survivors. Conclusion: Drotrecogin alfa (activated) demonstrated significant improvements in organ function compared with placebo in a large phase 3 clinical trial that has shown a mortality benefit in patients with severe sepsis.

Original languageEnglish (US)
Pages (from-to)834-840
Number of pages7
JournalCritical care medicine
Volume31
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Placebos
Organ Dysfunction Scores
Sepsis
Morbidity
Phase III Clinical Trials
drotrecogin alfa activated
Protein C
Recombinant Proteins
Survivors
Kidney
Mortality
Liver
Therapeutics

Keywords

  • Activated protein C
  • Drotrecogin alfa (activated)
  • Morbidity
  • Organ dysfunction
  • Sepsis
  • Sequential Organ Failure Assessment

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Vincent, J. L., Angus, D. C., Artigas, A., Kalil, A. C., Basson, B. R., Jamal, H. H., ... Bernard, G. R. (2003). Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Critical care medicine, 31(3), 834-840. https://doi.org/10.1097/01.CCM.0000051515.56179.E1

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. / Vincent, Jean Louis; Angus, Derek C.; Artigas, Antonio; Kalil, Andre C; Basson, Bruce R.; Jamal, Hassan H.; Johnson, Gerald; Bernard, Gordon R.

In: Critical care medicine, Vol. 31, No. 3, 01.03.2003, p. 834-840.

Research output: Contribution to journalArticle

Vincent, JL, Angus, DC, Artigas, A, Kalil, AC, Basson, BR, Jamal, HH, Johnson, G & Bernard, GR 2003, 'Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial', Critical care medicine, vol. 31, no. 3, pp. 834-840. https://doi.org/10.1097/01.CCM.0000051515.56179.E1
Vincent, Jean Louis ; Angus, Derek C. ; Artigas, Antonio ; Kalil, Andre C ; Basson, Bruce R. ; Jamal, Hassan H. ; Johnson, Gerald ; Bernard, Gordon R. / Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. In: Critical care medicine. 2003 ; Vol. 31, No. 3. pp. 834-840.
@article{727dd4a63a3b4696898547e6e58bd29e,
title = "Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial",
abstract = "Objective: To assess morbidity in patients with severe sepsis managed with and without drotrecogin alfa (activated). Design: Analysis of secondary end points in a prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (PROWESS). Setting: A total of 164 medical institutions in 11 countries. Patients: A total of 1,690 consecutive adult patients with severe sepsis. Interventions: A 96-hr infusion of drotrecogin alfa (activated) (human recombinant activated protein C) or placebo. Measurements and Main Results: Sequential Organ Failure Assessment (SOFA) scores for cardiovascular, respiratory, renal, hematologic, and hepatic organ systems were measured for 28 days. Mean cardiovascular SOFA scores were significantly lower for patients treated with drotrecogin alfa (activated) compared with placebo patients over this time period (p = .022). Drotrecogin alfa (activated)-treated patients also showed significantly faster resolution of cardiovascular (p = .009) and respiratory (p = .009) dysfunction and significantly slower onset of hematologic organ dysfunction (p = .041) compared with placebo patients for days 1 to 7. No significant differences in morbidity were observed between treatment groups among 28-day survivors. Conclusion: Drotrecogin alfa (activated) demonstrated significant improvements in organ function compared with placebo in a large phase 3 clinical trial that has shown a mortality benefit in patients with severe sepsis.",
keywords = "Activated protein C, Drotrecogin alfa (activated), Morbidity, Organ dysfunction, Sepsis, Sequential Organ Failure Assessment",
author = "Vincent, {Jean Louis} and Angus, {Derek C.} and Antonio Artigas and Kalil, {Andre C} and Basson, {Bruce R.} and Jamal, {Hassan H.} and Gerald Johnson and Bernard, {Gordon R.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1097/01.CCM.0000051515.56179.E1",
language = "English (US)",
volume = "31",
pages = "834--840",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial

AU - Vincent, Jean Louis

AU - Angus, Derek C.

AU - Artigas, Antonio

AU - Kalil, Andre C

AU - Basson, Bruce R.

AU - Jamal, Hassan H.

AU - Johnson, Gerald

AU - Bernard, Gordon R.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Objective: To assess morbidity in patients with severe sepsis managed with and without drotrecogin alfa (activated). Design: Analysis of secondary end points in a prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (PROWESS). Setting: A total of 164 medical institutions in 11 countries. Patients: A total of 1,690 consecutive adult patients with severe sepsis. Interventions: A 96-hr infusion of drotrecogin alfa (activated) (human recombinant activated protein C) or placebo. Measurements and Main Results: Sequential Organ Failure Assessment (SOFA) scores for cardiovascular, respiratory, renal, hematologic, and hepatic organ systems were measured for 28 days. Mean cardiovascular SOFA scores were significantly lower for patients treated with drotrecogin alfa (activated) compared with placebo patients over this time period (p = .022). Drotrecogin alfa (activated)-treated patients also showed significantly faster resolution of cardiovascular (p = .009) and respiratory (p = .009) dysfunction and significantly slower onset of hematologic organ dysfunction (p = .041) compared with placebo patients for days 1 to 7. No significant differences in morbidity were observed between treatment groups among 28-day survivors. Conclusion: Drotrecogin alfa (activated) demonstrated significant improvements in organ function compared with placebo in a large phase 3 clinical trial that has shown a mortality benefit in patients with severe sepsis.

AB - Objective: To assess morbidity in patients with severe sepsis managed with and without drotrecogin alfa (activated). Design: Analysis of secondary end points in a prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (PROWESS). Setting: A total of 164 medical institutions in 11 countries. Patients: A total of 1,690 consecutive adult patients with severe sepsis. Interventions: A 96-hr infusion of drotrecogin alfa (activated) (human recombinant activated protein C) or placebo. Measurements and Main Results: Sequential Organ Failure Assessment (SOFA) scores for cardiovascular, respiratory, renal, hematologic, and hepatic organ systems were measured for 28 days. Mean cardiovascular SOFA scores were significantly lower for patients treated with drotrecogin alfa (activated) compared with placebo patients over this time period (p = .022). Drotrecogin alfa (activated)-treated patients also showed significantly faster resolution of cardiovascular (p = .009) and respiratory (p = .009) dysfunction and significantly slower onset of hematologic organ dysfunction (p = .041) compared with placebo patients for days 1 to 7. No significant differences in morbidity were observed between treatment groups among 28-day survivors. Conclusion: Drotrecogin alfa (activated) demonstrated significant improvements in organ function compared with placebo in a large phase 3 clinical trial that has shown a mortality benefit in patients with severe sepsis.

KW - Activated protein C

KW - Drotrecogin alfa (activated)

KW - Morbidity

KW - Organ dysfunction

KW - Sepsis

KW - Sequential Organ Failure Assessment

UR - http://www.scopus.com/inward/record.url?scp=0037352375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037352375&partnerID=8YFLogxK

U2 - 10.1097/01.CCM.0000051515.56179.E1

DO - 10.1097/01.CCM.0000051515.56179.E1

M3 - Article

VL - 31

SP - 834

EP - 840

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 3

ER -